JP2017507943A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507943A5
JP2017507943A5 JP2016553897A JP2016553897A JP2017507943A5 JP 2017507943 A5 JP2017507943 A5 JP 2017507943A5 JP 2016553897 A JP2016553897 A JP 2016553897A JP 2016553897 A JP2016553897 A JP 2016553897A JP 2017507943 A5 JP2017507943 A5 JP 2017507943A5
Authority
JP
Japan
Prior art keywords
composition
item
neu
osteosarcoma
listeria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016553897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507943A (ja
Filing date
Publication date
Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Application filed filed Critical
Priority claimed from PCT/US2015/017559 external-priority patent/WO2015130810A2/fr
Publication of JP2017507943A publication Critical patent/JP2017507943A/ja
Publication of JP2017507943A5 publication Critical patent/JP2017507943A5/ja
Pending legal-status Critical Current

Links

JP2016553897A 2014-02-25 2015-02-25 Ｈｅｒ２／ｎｅｕ過剰発現腫瘍の治療のための組成物および方法 Pending JP2017507943A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14/189,008 2014-02-25
US14/189,008 US20150366955A9 (en) 2009-11-11 2014-02-25 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 2014-05-02
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
US62/076,411 2014-11-06
PCT/US2015/017559 WO2015130810A2 (fr) 2014-02-25 2015-02-25 Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu

Publications (2)

Publication Number Publication Date
JP2017507943A JP2017507943A (ja) 2017-03-23
JP2017507943A5 true JP2017507943A5 (fr) 2018-08-02

Family

ID=54009773

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553897A Pending JP2017507943A (ja) 2014-02-25 2015-02-25 Ｈｅｒ２／ｎｅｕ過剰発現腫瘍の治療のための組成物および方法

Country Status (12)

Country Link
EP (1) EP3110942A4 (fr)
JP (1) JP2017507943A (fr)
KR (2) KR20240038103A (fr)
CN (1) CN106661538A (fr)
AU (1) AU2015223136A1 (fr)
BR (1) BR112016019534A2 (fr)
CA (1) CA2940646A1 (fr)
IL (1) IL247436A0 (fr)
MX (1) MX2016011114A (fr)
RU (1) RU2016137834A (fr)
SG (1) SG11201607036XA (fr)
WO (1) WO2015130810A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CA2829960A1 (fr) 2011-03-11 2012-09-20 John Rothman Adjuvants a base de listeria
WO2013138337A1 (fr) 2012-03-12 2013-09-19 Advaxis Inhibition de la fonction des cellules suppresseurs après traitement par un vaccin à base de listeria
JP2017511796A (ja) 2014-02-18 2017-04-27 アドバクシス， インコーポレイテッド 多標的免疫療法を目的とするバイオマーカー
AU2015227163A1 (en) * 2014-03-05 2016-10-20 Advaxis, Inc. Methods and compositions for increasing a T-effector cell to regulatory T cell ratio
EP3134510B1 (fr) 2014-04-24 2023-11-01 Advaxis, Inc. Souches de listeria utilisées comme vaccin recombinant et procédé de production
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
CA3035591A1 (fr) 2016-11-30 2018-06-07 Advaxis, Inc. Compositions immunogenes ciblant des mutations recurrentes du cancer et leurs procedes d'utilisation
AU2018336988B2 (en) 2017-09-19 2023-06-22 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or Listeria strains
EP4576103A3 (fr) 2017-10-10 2025-08-27 Gritstone bio, Inc. Identification de néoantigènes à l'aide de points chauds
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors

Similar Documents

Publication Publication Date Title
JP2017507943A5 (fr)
JP2013526837A5 (fr)
RU2016137834A (ru) КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu
US9969986B2 (en) Virus like particle comprising modified envelope protein E3
JP6538622B2 (ja) ホモ二量体タンパク質コンストラクト
KR102713707B1 (ko) 신규 다가 나노입자 기반 백신
JP2017195888A5 (fr)
ES2675825T3 (es) Vacunación tumoral que involucra una respuesta inmunitaria contra la proteína propia CLDN18.2
JP2017513502A5 (fr)
JP2018508212A5 (fr)
JP2016156828A5 (fr)
US20160200775A1 (en) Virus like particle comprising modified envelope protein e3
CN118576699A (zh) Hbv疫苗
KR20170092626A (ko) 재조합 리스테리아 균주의 병용 요법
AU2017211387A1 (en) Personalized delivery vector-based immunotherapy and uses thereof
JP6406647B2 (ja) 細胞性免疫誘導ワクチン
Fioretti et al. Recent advances in design of immunogenic and effective naked DNA vaccines against cancer
CN115397462A (zh) 个体化治疗性抗癌疫苗
KR20240024800A (ko) 암호화된 아주반트를 포함하는 백신 조성물
US11844824B2 (en) Nucleic acid molecules and methods of using the same
JP2024054375A (ja) エキソソーム標的ｄｎａワクチン
NZ723750B2 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
Bequet-Romero et al. Mutated variant of human vascular endothelial growth factor as a vaccine candidate for cancer immunotherapy